The impact of tumor location on the value of lymphadenectomy for intrahepatic cholangiocarcinoma.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
06 2023
Historique:
received: 16 11 2022
revised: 07 01 2023
accepted: 20 02 2023
medline: 5 6 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

The therapeutic role of lymphadenectomy (LND) for intrahepatic cholangiocarcinoma (ICC) patients remains ill-defined. We sought to analyze the therapeutic value of LND relative to tumor location and preoperative lymph node metastasis (LNM) risk. Patients who underwent curative-intent hepatic resection of ICC between 1990 and 2020 were included from a multi-institutional database. Therapeutic LND (tLND) was defined as LND that harvested ≥3 lymph nodes. Among 662 patients, 178 (26.9%) individuals received tLND. Patients were categorized into central type ICC (n = 156, 23.6%) and peripheral type ICC (n = 506, 76.4%). Central type harbored multiple adverse clinicopathologic factors and worse overall survival (OS) compared with peripheral type (5-year OS, central: 27.0% vs. peripheral: 47.2%, p < 0.001). After consideration of preoperative LNM risk, patients with central type and high-risk LNM who underwent tLND survived longer than individuals who did not (5-year OS, tLND: 27.9% vs. non-tLND: 9.0%, p = 0.001), whereas tLND was not associated with better survival among patients with peripheral type ICC or low-risk LNM. The therapeutic index of hepatoduodenal ligament (HDL) and other regions was higher in central type than in peripheral type, which was more pronounced among high-risk LNM patients. Central type ICC with high-risk LNM should undergo LND involving regions beyond the HDL.

Sections du résumé

BACKGROUND
The therapeutic role of lymphadenectomy (LND) for intrahepatic cholangiocarcinoma (ICC) patients remains ill-defined. We sought to analyze the therapeutic value of LND relative to tumor location and preoperative lymph node metastasis (LNM) risk.
METHODS
Patients who underwent curative-intent hepatic resection of ICC between 1990 and 2020 were included from a multi-institutional database. Therapeutic LND (tLND) was defined as LND that harvested ≥3 lymph nodes.
RESULTS
Among 662 patients, 178 (26.9%) individuals received tLND. Patients were categorized into central type ICC (n = 156, 23.6%) and peripheral type ICC (n = 506, 76.4%). Central type harbored multiple adverse clinicopathologic factors and worse overall survival (OS) compared with peripheral type (5-year OS, central: 27.0% vs. peripheral: 47.2%, p < 0.001). After consideration of preoperative LNM risk, patients with central type and high-risk LNM who underwent tLND survived longer than individuals who did not (5-year OS, tLND: 27.9% vs. non-tLND: 9.0%, p = 0.001), whereas tLND was not associated with better survival among patients with peripheral type ICC or low-risk LNM. The therapeutic index of hepatoduodenal ligament (HDL) and other regions was higher in central type than in peripheral type, which was more pronounced among high-risk LNM patients.
CONCLUSIONS
Central type ICC with high-risk LNM should undergo LND involving regions beyond the HDL.

Identifiants

pubmed: 36894491
pii: S1365-182X(23)00052-7
doi: 10.1016/j.hpb.2023.02.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

650-658

Informations de copyright

Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Yutaka Endo (Y)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Zorays Moazzam (Z)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Henrique A Lima (HA)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Laura Alaimo (L)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; Department of Surgery, University of Verona, Verona, Italy.

Muhammad M Munir (MM)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Chanza F Shaikh (CF)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Alfredo Guglielmi (A)

Department of Surgery, University of Verona, Verona, Italy.

Luca Aldrighetti (L)

Department of Surgery, Ospedale San Raffaele, Milan, Italy.

Matthew Weiss (M)

Department of Surgery, John Hopkins Hospital, Baltimore, MD, USA.

Todd W Bauer (TW)

Department of Surgery, University of Virginia, Charlottesville, VA, USA.

Sorin Alexandrescu (S)

Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.

George A Poultsides (GA)

Department of Surgery, Stanford University, Stanford, CA, USA.

Minoru Kitago (M)

Department of Surgery, Keio University, Tokyo, Japan.

Shishir K Maithel (SK)

Department of Surgery, Emory University, Atlanta, GA, USA.

Hugo P Marques (HP)

Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

Guillaume Martel (G)

Department of Surgery, University of Ottawa, Ottawa, ON, Canada.

Carlo Pulitano (C)

Department of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.

Feng Shen (F)

Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

François Cauchy (F)

Department of Hepatobiliopancreatic Surgery, APHP, Beaujon Hospital, Clichy, France.

Bas G Koerkamp (BG)

Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands.

Itaru Endo (I)

Department of Gastroenterological Surgery, Yokohama City, University School of Medicine, Yokohama, Japan.

Timothy M Pawlik (TM)

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: tim.Pawlik@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH